Triple therapy aims to cure High-Risk skin cancer without disfigurement

NCT ID NCT07251413

Recruiting now ⭐️ CURE ⭐️ Sponsor: Instituto Oncológico Dr Rosell Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining an immunotherapy drug (cemiplimab), a topical cream (imiquimod), and laser therapy before surgery can cure high-risk basal cell skin cancer. About 18 adults with large or difficult-to-treat tumors will receive the combination or immunotherapy alone. The goal is to increase the chance of a definitive cure and reduce the need for disfiguring surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS BASAL CELL CARCINOMA

Contacts and locations

Locations

Hospital Clínic de Barcelona. Carrer de Villarroel, 170, L'Eixample
RECRUITING

Barcelona, Barcelona, 08036, Spain
Hospital Miguel Servet de Zaragoza. P.º de Isabel la Católica, 1-3
RECRUITING

Zaragoza, Zaragoza, 5009, Spain
Hospital Ramón y Cajal. M-607, Km. 9, 100, Fuencarral-El Pardo,
RECRUITING

Madrid, Madrid, 28034, Spain
Hospital Universitario Dexeus - Grupo Quirónsalud. Carrer de Sabino Arana, 19 Ed, Distrito de Les Corts
RECRUITING

Barcelona, Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.